Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Cumberland Pharmaceuticals Inc (CPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: CPIX (1-star) is a SELL. SELL since 1 days. Profits (-14.37%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 20.54% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 80.19M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 44495 | Beta -0.29 | 52 Weeks Range 1.04 - 7.25 | Updated Date 06/22/2025 |
52 Weeks Range 1.04 - 7.25 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.98% | Operating Margin (TTM) 11.03% |
Management Effectiveness
Return on Assets (TTM) -2.7% | Return on Equity (TTM) -11.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75207760 | Price to Sales(TTM) 1.97 |
Enterprise Value 75207760 | Price to Sales(TTM) 1.97 | ||
Enterprise Value to Revenue 1.84 | Enterprise Value to EBITDA 23.21 | Shares Outstanding 14961100 | Shares Floating 7940923 |
Shares Outstanding 14961100 | Shares Floating 7940923 | ||
Percent Insiders 41.54 | Percent Institutions 28.76 |
Analyst Ratings
Rating 5 | Target Price 8.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cumberland Pharmaceuticals Inc
Company Overview
History and Background
Cumberland Pharmaceuticals Inc. was founded in 1999 and is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products. Initially focused on hospital products, it has expanded its portfolio through acquisitions and internal development.
Core Business Areas
- Acute Care: Focuses on hospital-based products to address critical care needs, including pain management and cardiovascular support.
- Gastroenterology: Offers products aimed at treating various gastrointestinal disorders.
- Dermatology: Provides treatments for dermatological conditions.
Leadership and Structure
The company is led by CEO John Hammann. The organizational structure includes departments for research and development, sales and marketing, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- Vaprisol: Vaprisol (conivaptan) is used to treat hyponatremia (low sodium levels in the blood). Competitors include generic saline solutions and other vasopressin receptor antagonists. Revenue is not publicly broken down per product.
- Caldolor: Caldolor (ibuprofen) injection for pain and fever. Competitors include Ofirmev (acetaminophen) and generic ibuprofen formulations. Revenue is not publicly broken down per product.
- Ofev: Ofev is a solution that treats moderate to severe opioid-induced constipation in adult patients. Competitors include Amitiza, Relistor. Revenue is not publicly broken down per product.
Market Dynamics
Industry Overview
The specialty pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and competition from generic drugs. Demand is driven by an aging population and increasing prevalence of chronic diseases.
Positioning
Cumberland Pharmaceuticals Inc. occupies a niche position, targeting specific unmet medical needs with branded products. Its competitive advantage lies in its portfolio of established brands and its ability to acquire and commercialize undervalued assets.
Total Addressable Market (TAM)
The TAM for Cumberland's products spans acute care, GI, and dermatology markets, amounting to billions of dollars annually. Cumberland captures a small fraction, focusing on specific niches within these larger markets.
Upturn SWOT Analysis
Strengths
- Established brands with proven efficacy
- Strong hospital presence
- Experienced management team
- Proprietary products
Weaknesses
- Reliance on a limited number of products
- Vulnerability to generic competition
- Relatively small market capitalization
- High operating expenses
Opportunities
- Acquisitions of complementary products
- Expansion into new therapeutic areas
- Strategic partnerships
- Geographic expansion
Threats
- Generic erosion
- Increased regulatory scrutiny
- Competition from larger pharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Mallinckrodt (MNK)
- Endo International (ENDPQ)
- Amneal Pharmaceuticals (AMRX)
Competitive Landscape
Cumberland faces competition from larger, more diversified pharmaceutical companies. Its advantages lie in its specialized focus and established brands. Disadvantages include limited resources and vulnerability to generic competition. The numbers are estimates of market share and are used to demonstrate the format.
Major Acquisitions
Ithem Medical
- Year: 2016
- Acquisition Price (USD millions): 17.5
- Strategic Rationale: Acquisition of Ithem Medical was to expand the portfolio in hospital acute care area.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, driven by product sales and acquisitions.
Future Projections: Future growth is projected to depend on the successful commercialization of new products and the acquisition of additional assets.
Recent Initiatives: Recent initiatives include the development of new formulations and the pursuit of strategic partnerships.
Summary
Cumberland Pharmaceuticals is a niche specialty pharmaceutical company with established brands. It faces challenges from generic competition and requires strategic acquisitions for growth. The company needs to focus on innovation and manage its expenses effectively. Its hospital presence and brand recognition are key strengths, but vulnerability to generics remains a significant concern. The company has relatively small market share in comparison to some competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- SEC Filings
- Market Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cumberland Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2009-08-11 | Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 91 | Website https://www.cumberlandpharma.com |
Full time employees 91 | Website https://www.cumberlandpharma.com | ||
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.